Treatment of knee osteoarthritis with Orthokine^®-derived autologous conditioned serum

References

• Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull. World Health Organ.81, 646–656 (2003).
   PubMed Web of Science ®Google Scholar
• Keenan AM, Tennant A, Fear J et al. Impact of multiple joint problems on daily living tasks in people in the community over age fifty-five. Arthritis Rheum.55, 757–764 (2006).
   PubMed Web of Science ®Google Scholar
• Sprangers MA, de Regt EB, Andries F et al. Which chronic conditions are associated with better or poorer quality of life? J. Clin. Epidemiol.53, 895–907 (2000).
   PubMed Web of Science ®Google Scholar
• Reginster J-Y. The prevalence and burden of arthritis. Rheumatology42(Suppl. 1), 3–6 (2002).
   Google Scholar
• Hannan MT, Felson DT, Pincus T. Analysis of the discordance between radiographic changes and knee pain in osteoarthritis of the knee. J. Rheumatol.27, 1513–1517 (2000).
   PubMed Web of Science ®Google Scholar
• Hootman JM, Helmick DG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum.54, 226–229 (2006).
   PubMed Web of Science ®Google Scholar
• Ethgen O, Reginster J-Y. Degenerative musculoskeletal disease. Ann. Rheum. Dis.63, 1–3 (2004).
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Felson DT, Helmick CG et al. Estimates of prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum.58(1), 26–35 (2008).
   PubMed Web of Science ®Google Scholar
• Felson DT. Clinical practice: osteoarthritis of the knee. N. Engl. J. Med.354, 841–848 (2006).
   PubMedGoogle Scholar
• Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum.53, 673–681 (2005).
   PubMed Web of Science ®Google Scholar
• Mapel DW, Shainline M, Paez K, Gunter M. Hospital, pharmacy, and outpatient costs for osteoarthritis and chronic back pain. J. Rheumatol.31, 573–583 (2004).
   PubMed Web of Science ®Google Scholar
• Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum.41(8), 1343–1355 (1998).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Niu J, Zhang Y et al. Knee height, knee pain, and knee osteoarthritis: the Beijing Osteoarthritis Study. Arthritis Rheum.52(5), 1418–1423 (2005).
   PubMedGoogle Scholar
• Rapp SR, Rejeski WJ, Miller ME. Physical function among older adults with knee pain: the role of pain coping skills. Arthritis Care Res.13(5), 270–279 (2000).
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Crowson CS, Campion ME, O’Fallon WM. Direct medical costs unique to people with arthritis. J. Rheumatol.24, 719–725 (1997).
   PubMed Web of Science ®Google Scholar
• Gupta S, Hawker GA, Laporte A, Croxford R, Coyte PC. The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition. Rheumatology44, 1531–1537 (2005).
   PubMed Web of Science ®Google Scholar
• Maetzel A, Li LC, Pencharz J et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann. Rheum. Dis.63, 395–401 (2004).
   PubMed Web of Science ®Google Scholar
• CDC. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions – United States, 2003. MMWR Morb. Mortal. Wkly Rep.56(1), 4–7 (2007).
   PubMedGoogle Scholar
• Jordan KM, Arden NK, Doherty M et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann. Rheum. Dis.62, 1145–1155 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part 1: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage15, 981–1000 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage16(2), 137–162 (2008).
   PubMed Web of Science ®Google Scholar
• Watkins PB, Kaplowitz N, Slattery JT et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA296(1), 87–93 (2006).
   PubMed Web of Science ®Google Scholar
• Bellamy N, Campbell J, Robinson V et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst. Rev.2(2), CD005328 (2005).
   Google Scholar
• Towheed TE, Maxwell L, Anastassiades TP et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst. Rev.2(2), CD002946 (2005).
   Google Scholar
• Fox BA, Stephens MM. Glucosamine hydrochloride for the treatment of osteoarthritis symptoms. Clin. Interv. Aging2(4), 599–604 (2007).
   PubMed Web of Science ®Google Scholar
• Fajardo M, Di Cesare PE. Disease-modifying therapies for osteoarthritis. Drugs Aging22(2), 141–161 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology39(1–2), 237–246 (2002).
   PubMed Web of Science ®Google Scholar
• Pelletier JP, McCollum R, Cloutier JM, Martel-Pelletier J. Synthesis of metalloproteases and interleukin 6 (IL-6) in human osteoarthritic synovial membrane is an IL-1 mediated process. J. Rheumatol.22(Suppl. 43), 109–114 (1995).
   PubMed Web of Science ®Google Scholar
• Krasnokutsky S, Attur M, Palmer G, Samuels J, Abramson SB. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage16, S1–S3 (2008).
   Web of Science ®Google Scholar
• Abramson SB, Attur M. Developments in the scientific understanding of osteoarthritis. Arthritis Res. Ther.11, 227 (2009).
   PubMed Web of Science ®Google Scholar
• Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol.27, 519–550 (2009).
   PubMed Web of Science ®Google Scholar
• Fukui N, Purple CR, Sandell LJ. Cell biology of osteoarthritis: the chondrocyte’s response to injury. Curr. Rheumatol. Rep.3(6), 496–505 (2001).
   PubMedGoogle Scholar
• Goldring MB. Osteoarthritis and cartilage: the role of cytokines. Curr. Rheumatol. Rep.2(6), 459–465 (2000).
   PubMedGoogle Scholar
• Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res. Ther.8(Suppl. 2), S3 (2006).
   PubMed Web of Science ®Google Scholar
• Arend WP, Leung DYM. IgG induction of IL-1 receptor antagonist production by human monocytes. Immunol. Rev.139, 71–78 (1994).
   PubMed Web of Science ®Google Scholar
• Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol.16, 27–35 (1998).
   PubMed Web of Science ®Google Scholar
• Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J. Clin. Invest.88, 1445–1451 (1991).
   PubMed Web of Science ®Google Scholar
• Firestein GS, Berger AE, Tracey DE et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J. Immunol.149(3), 1054–1062 (1992).
   PubMed Web of Science ®Google Scholar
• Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH. Gene transfer synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol.11(3), 227–231 (1992).
   PubMed Web of Science ®Google Scholar
• Bander G, Mueller GM, Galea-Lauri J et al. Intraarticular expression of biologically active interleukin-1 receptor-antagonist protein by ex vivo gene transfer. Proc. Natl Acad. Sci.99, 10764–10768 (1993).
   Google Scholar
• Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect. Tissue Res.40(1), 1–11 (1999).
   PubMed Web of Science ®Google Scholar
• Fernandes J, Tardiff, G, Martel-Pelletier J et al.In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritis rabbit knee joints. Am. J. Pathol.154(4), 1159–1169 (1999).
   PubMed Web of Science ®Google Scholar
• Frisbee DD, Ghivizzani SC, Robbins PD et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther.9(1), 12–20 (2002).
   PubMedGoogle Scholar
• Zhang X, Mao Z, Yu C. Suppression of early experimental osteoarthritis by gene transfer of interleukin-1 receptor antagonist and interleukin-10. J. Orthop. Res.22(4), 742–750 (2004).
   PubMed Web of Science ®Google Scholar
• Pelletier JP, Canon JP, Evans D et al.In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum.40(6), 1012–1029 (1997).
   PubMed Web of Science ®Google Scholar
• Chevalier X, Giraudeau B, Conrozier T et al. Safety study of intra-articular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol.32(7), 1317–1323 (2005).
   PubMed Web of Science ®Google Scholar
• Chevalier X, Gopille P, Beaulieu AD et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum.61(3), 344–352 (2009).
   PubMed Web of Science ®Google Scholar
• Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm. Res.52(10), 404–407 (2003).
   PubMed Web of Science ®Google Scholar
• Evans CH. Novel biological approaches to the intra-articular treatment of osteoarthritis. BioDrugs19(6), 355–362 (2005).
   PubMed Web of Science ®Google Scholar
• Wehling P, Moser C, Frisbee D et al. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs21(5), 323–332 (2007).
   PubMed Web of Science ®Google Scholar
• Wright-Carpenter T, Opolon P, Appell HJ, Meijer H, Wehling P, Mir LM. Treatment of muscle injuries by local administration of autologous conditioned serum: animal experiments using a muscle contusion model. Int. J. Sports Med.25, 582–587 (2004).
   PubMed Web of Science ®Google Scholar
• Wright-Carpenter T, Klein P, Schäferhoff P, Appell HJ, Mir LM, Wehling P. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int. J. Sports Med.25, 588–593 (2004).
   PubMed Web of Science ®Google Scholar
• Frisbee DD, Kawcak CE, McIlwraith CW. Evaluation of autologous conditioned serum using an experimental model of equine osteoarthritis. AAEP Proc. Lame. Perform. Horse51, 374–375 (2005).
   Google Scholar
• Frisbee DD, Kawcak CE, Werpy NM, Park RD, Mcllwraith CW. Clinical, biochemical, histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am. J. Vet. Res.68, 290–296 (2007).
   PubMedGoogle Scholar
• Weinberger T. Clinical experience with ACS/Orthokine/IRAP in horses. Equine Sports Med. Reprint3, 1–5 (2008).
   Google Scholar
• Osterdahl J. Evaluation of autologous conditioned serum. Swedish Uni. Agricultural Sci.67, 1–16 (2008).
   Google Scholar
• Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage17, 152–160 (2009).
   PubMed Web of Science ®Google Scholar
• Yang KGA, Raijmakers NJH, van Arkel ERA et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage16, 498–505 (2008).
   PubMed Web of Science ®Google Scholar
• Moser C, Baltzer AW, Jansen SA, Krauspe R. Efficacy of autologous conditioned serum (ACS-Orthokine) in osteoarthritis of the knee at two year follow-up. The German Orthokine Osteoarthritis Trial-GOAT. Osteoarthritis Cartilage15(Suppl. C), C233 (2007).
   Google Scholar
• Goldring MB, Goldring SR. Osteoarthritis. J. Cell. Physiol.213, 626–634 (2007).
   PubMed Web of Science ®Google Scholar
• Polisson R. Innovative therapies in osteoarthritis. Curr. Rheumatol. Rep.3(6), 489–496 (2001).
   PubMedGoogle Scholar
• Fidelis TS, Soares B, Trevisani FV. Diacerein for osteoarthritis. Cochrane Database Syst Rev.1(1), CD005117 (2006).
   Google Scholar
• Brandt KD, Mazzuca SA, Katz BP et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum.52(7), 2015–2015 (2005).
   PubMed Web of Science ®Google Scholar
• Nüesch E, Rutjes AW, Trelle S, Reichenbach S, Jüni P. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev.4(4), CD007323 (2009).
   Google Scholar
• Evans CH, Ghivizzani SC, Robbins PD. Progress and prospects: genetic treatments for disorders of bones and joints. Gene Ther.16(8), 944–952 (2009).
   PubMed Web of Science ®Google Scholar
• Blaney Davidson EN, van der Kraan PM, van den Berg WB. TGF-β and osteoarthritis. Osteoarthritis Cartilage15(6), 597–604 (2007).
   PubMed Web of Science ®Google Scholar
• Scharstuhl A, Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg WB.Inhibition of endogenous TGF-β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J. Immunol.169, 507–514 (2002).
   PubMed Web of Science ®Google Scholar
• Baragi VM, Becher G, Bendele AM et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis. Arthritis Rheum.60(7), 2008–2018 (2009).
   PubMed Web of Science ®Google Scholar